Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Cladribine in Relapsing MS (NOR-MS)
NCT04121403Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- Oct 2019
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in multiple sclerosis (MS) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Number of new or enlarging cerebral MRI T2 lesions. Started Oct 2019; status: completed.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04121403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121403.